Based on undisclosed data from an ongoing Phase I trial, Genentech Inc. decided to license rights to a 14-year-old technology that could allow the company to target a broad swath of cancer antigens that are impossible to hit with conventional antibodies and antibody-based strategies like chimeric antigen receptors and antibody-drug conjugates.

Under a deal announced last week, the Roche unit and Immunocore Ltd. will use the latter's technology to discover and develop bi-specific ImmTACs against an undisclosed number of cancer targets.